CRYBG2 and esophageal squamous cell carcinoma: Chemotherapy, molecular targeted therapy, and immunotherapy hold a pivotal position in the treatment of ESCC.[31] Therefore, we studied the correlation between AIM1L in ESCC and tumor-infiltrating immune cells, as well as some commonly used chemical drugs and molecularly targeted drugs.